These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 16516594)

  • 1. Proportion of patients followed in a specialized heart failure clinic needing an implantable cardioverter defibrillator as determined by applying different trial eligibility criteria.
    Toma M; McAlister FA; Ezekowitz J; Kimber S; Gulamhusein S; Pantano A; Sivakumaran S; Cujec B; Paterson I; Armstrong PW
    Am J Cardiol; 2006 Mar; 97(6):882-5. PubMed ID: 16516594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials.
    Ghanbari H; Dalloul G; Hasan R; Daccarett M; Saba S; David S; Machado C
    Arch Intern Med; 2009 Sep; 169(16):1500-6. PubMed ID: 19752408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implantable cardioverter-defibrillator efficacy in patients with heart failure and left ventricular dysfunction (from the MADIT II population).
    Zareba W; Piotrowicz K; McNitt S; Moss AJ;
    Am J Cardiol; 2005 Jun; 95(12):1487-91. PubMed ID: 15950580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MADIT II, the Multi-center Autonomic Defibrillator Implantation Trial II stopped early for mortality reduction, has ICD therapy earned its evidence-based credentials?
    Coats AJ
    Int J Cardiol; 2002 Jan; 82(1):1-5. PubMed ID: 11786150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in patients with left ventricular systolic dysfunction: 14 years after MADIT.
    Franqui-Rivera H; Sotomonte JC
    P R Health Sci J; 2011 Jun; 30(2):78-83. PubMed ID: 21682151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Causes and consequences of heart failure after prophylactic implantation of a defibrillator in the multicenter automatic defibrillator implantation trial II.
    Goldenberg I; Moss AJ; Hall WJ; McNitt S; Zareba W; Andrews ML; Cannom DS;
    Circulation; 2006 Jun; 113(24):2810-7. PubMed ID: 16769917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biventricular pacing and defibrillator use in chronic heart failure.
    Cesario DA; Turner JW; Dec GW
    Cardiol Clin; 2007 Nov; 25(4):595-603; vii. PubMed ID: 18063163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of implantable cardioverter defibrillators for primary prevention in the community: do women and men equally meet trial enrollment criteria?
    Daugherty SL; Peterson PN; Wang Y; Curtis JP; Heidenreich PA; Lindenfeld J; Vidaillet HJ; Masoudi FA;
    Am Heart J; 2009 Aug; 158(2):224-9. PubMed ID: 19619698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: a pooled analysis of 10 primary prevention trials.
    Nanthakumar K; Epstein AE; Kay GN; Plumb VJ; Lee DS
    J Am Coll Cardiol; 2004 Dec; 44(11):2166-72. PubMed ID: 15582314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implantable cardioverter defibrillator for primary prevention in patients with severe ventricular dysfunction awaiting heart transplantation.
    Cantero-Pérez EM; Sobrino-Márquez JM; Grande-Trillo A; Lage-Gallé E; Rangel-Sousa D; Esteve-Ruiz IM; Martínez-Martínez A
    Transplant Proc; 2013; 45(10):3659-61. PubMed ID: 24314988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Risk stratification and prevention of sudden death in patients with heart failure].
    Villacastín J; Bover R; Castellano NP; Moreno J; Morales R; García-Espinosa A
    Rev Esp Cardiol; 2004 Aug; 57(8):768-82. PubMed ID: 15282066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac resynchronization therapy in patients with end-stage inotrope-dependent class IV heart failure.
    Herweg B; Ilercil A; Cutro R; Dewhurst R; Krishnan S; Weston M; Barold SS
    Am J Cardiol; 2007 Jul; 100(1):90-3. PubMed ID: 17599447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of implantable-cardioverter-defibrillator trials on clinical management of patients with heart failure.
    Winslow RD; Pinney S; Fuster V
    Nat Clin Pract Cardiovasc Med; 2006 Feb; 3(2):86-93. PubMed ID: 16446777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ABCD (Alternans Before Cardioverter Defibrillator) Trial: strategies using T-wave alternans to improve efficiency of sudden cardiac death prevention.
    Costantini O; Hohnloser SH; Kirk MM; Lerman BB; Baker JH; Sethuraman B; Dettmer MM; Rosenbaum DS;
    J Am Coll Cardiol; 2009 Feb; 53(6):471-9. PubMed ID: 19195603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of a microvolt T-wave alternans screening strategy for implantable cardioverter-defibrillator placement in the MADIT-II-eligible population.
    Chan PS; Stein K; Chow T; Fendrick M; Bigger JT; Vijan S
    J Am Coll Cardiol; 2006 Jul; 48(1):112-21. PubMed ID: 16814657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relations among renal function, risk of sudden cardiac death, and benefit of the implanted cardiac defibrillator in patients with ischemic left ventricular dysfunction.
    Goldenberg I; Moss AJ; McNitt S; Zareba W; Andrews ML; Hall WJ; Greenberg H; Case RB;
    Am J Cardiol; 2006 Aug; 98(4):485-90. PubMed ID: 16893702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary prevention of sudden cardiac death using implantable cardioverter defibrillators.
    Ding L; Hua W; Niu H; Chen K; Zhang S
    Europace; 2008 Sep; 10(9):1034-41. PubMed ID: 18559335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Death without prior appropriate implantable cardioverter-defibrillator therapy: a competing risk study.
    Koller MT; Schaer B; Wolbers M; Sticherling C; Bucher HC; Osswald S
    Circulation; 2008 Apr; 117(15):1918-26. PubMed ID: 18391108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of gender on survival amongst patients with implantable cardioverter defibrillators for primary prevention against sudden cardiac death.
    Henyan NN; White CM; Gillespie EL; Smith K; Coleman CI; Kluger J
    J Intern Med; 2006 Nov; 260(5):467-73. PubMed ID: 17040253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trial-generated profiles for implantation of electrical devices in outpatients with heart failure: real-world prevalence and 1-year outcome.
    Boriani G; Rapezzi C; Diemberger I; Gonzini L; Gorini M; Lucci D; Sinagra G; Cooke RM; Di Pasquale G; Tavazzi L; Maggioni AP
    J Eval Clin Pract; 2010 Feb; 16(1):82-91. PubMed ID: 19874436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.